With this in mind, the researchers looked for a potential biomarker, landing on the chemokine receptor type 2 (CCR2). They then developed a new PET tracer—64Cu-DOTA-ECL1i—to image this particular receptor.
It’s the first of its kind, the researchers noted, and was confirmed to be safe and effective for imaging CCR2 in AAA patients.
Additionally, Heo and co-authors used the novel radiopharmaceutical to assess CCR2-targeted treatment in animals with AAA ruptures. For these preclinical tests, the PET tracer proved “highly suggestive” of predicting whether an aneurysm would burst.
The group also showed, in another animal cohort, that CCR2 inhibitor therapy effectively prevented AAA ruptures. This technique is likely applicable to humans, according to Heo et al.
“Given the availability of CCR2 inhibitors for human uses, our work holds great potential to assess AAA vulnerability, screen AAA patients for CCR2-targeted treatment, and determine treatment response for optimal outcome,” the WashUMed doctor explained.
"occur" - Google News
June 16, 2021 at 07:24AM
https://ift.tt/3gEnJTB
Imaging tracer spots deadly AAAs—potentially before life-threatening ruptures occur - Health Imaging
"occur" - Google News
https://ift.tt/2UoDqVw
https://ift.tt/2Wq6qvt
Bagikan Berita Ini
0 Response to "Imaging tracer spots deadly AAAs—potentially before life-threatening ruptures occur - Health Imaging"
Post a Comment